Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Depreciation and Depletion: 2011-2025

Historic Depreciation and Depletion for Mimedx Group (MDXG) over the last 14 years, with Sep 2025 value amounting to $572,000.

  • Mimedx Group's Depreciation and Depletion fell 1.38% to $572,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1.26%. This contributed to the annual value of $2.3 million for FY2024, which is 14.48% down from last year.
  • Mimedx Group's Depreciation and Depletion amounted to $572,000 in Q3 2025, which was up 1.78% from $562,000 recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's Depreciation and Depletion peaked at $1.3 million during Q2 2021, and registered a low of $558,000 during Q1 2024.
  • In the last 3 years, Mimedx Group's Depreciation and Depletion had a median value of $576,000 in 2024 and averaged $605,900.
  • In the last 5 years, Mimedx Group's Depreciation and Depletion slumped by 41.06% in 2021 and then increased by 0.72% in 2025.
  • Mimedx Group's Depreciation and Depletion (Quarterly) stood at $973,000 in 2021, then fell by 18.19% to $796,000 in 2022, then decreased by 23.24% to $611,000 in 2023, then declined by 7.69% to $564,000 in 2024, then declined by 1.38% to $572,000 in 2025.
  • Its last three reported values are $572,000 in Q3 2025, $562,000 for Q2 2025, and $564,000 during Q4 2024.